These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 22780968

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Down-regulation of hematopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid leukemia.
    Yang H, Liang H, Yan JS, Tao R, Hao SG, Ma LY.
    Int J Hematol; 2012 Jul; 96(1):65-73. PubMed ID: 22674382
    [Abstract] [Full Text] [Related]

  • 3. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
    Liu XL, Zhou SY, Du QF, Zheng WY, Zhang S, Song LL, Xu B, Liu QF, Meng FY.
    Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
    [Abstract] [Full Text] [Related]

  • 4. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS, Liu DS, Dai CW, Li RJ.
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [Abstract] [Full Text] [Related]

  • 5. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
    Gutiérrez-Castellanos S, Cruz M, Rabelo L, Godínez R, Reyes-Maldonado E, Riebeling-Navarro C.
    Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
    [Abstract] [Full Text] [Related]

  • 6. Molecular characterization and prognostic significance of FLT3 in CML progression.
    Kim KI, Park J, Ahn KS, Won NH, Kim BK, Shin WG, Yoon SS, Oh JM.
    Leuk Res; 2010 Aug; 34(8):995-1001. PubMed ID: 20031210
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Epigenetic inactivation of PLCD1 in chronic myeloid leukemia.
    Song JJ, Liu Q, Li Y, Yang ZS, Yang L, Xiang TX, Ren GS, Chen JB.
    Int J Mol Med; 2012 Jul; 30(1):179-84. PubMed ID: 22576628
    [Abstract] [Full Text] [Related]

  • 12. [Study on mismatch repair genes of chronic myeloid leukemia].
    Luo J, Peng ZG, Chen Y, Lai YR, Lu YY, Song SJ.
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):103-6. PubMed ID: 16732964
    [Abstract] [Full Text] [Related]

  • 13. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD.
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [Abstract] [Full Text] [Related]

  • 14. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
    Park J, Kim KI, Koh Y, Won NH, Oh JM, Lee DS, Kim BK, Ahn KS, Yoon SS.
    Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
    [Abstract] [Full Text] [Related]

  • 15. Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
    Wang Q, Zhou HS, Huang KK, Jiang XJ, Wu FQ, Cao R, Yin CX, Liao LB, Zheng ZX, He H, Lin R, Yi ZS, Xu D, Yang M, Meng FY.
    Int J Oncol; 2012 Feb; 40(2):418-26. PubMed ID: 22002244
    [Abstract] [Full Text] [Related]

  • 16. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K.
    Cancer Res; 2002 Oct 15; 62(20):5761-9. PubMed ID: 12384536
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
    Fajkusová L, Fajkus J, Polácková K, Fulnecek J, Dvoráková D, Krahulcová E.
    Blood Cells Mol Dis; 2000 Jun 15; 26(3):193-204. PubMed ID: 10950939
    [Abstract] [Full Text] [Related]

  • 19. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
    Okabe M.
    Hokkaido Igaku Zasshi; 1993 Mar 15; 68(2):237-50. PubMed ID: 8509066
    [Abstract] [Full Text] [Related]

  • 20. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
    Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, Hrisinko MA, Peterson LC.
    Am J Clin Pathol; 2003 Jun 15; 119(6):833-41. PubMed ID: 12817431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.